Emphasis on the laboratory testing of biomarkers for autoimmune nephropathies and lung diseases and the clinical promotion of their application
10.3760/cma.j.cn114452-20240716-00376
- VernacularTitle:重视自身免疫性肾病、肺病生物标志物实验室检查及临床推广应用
- Author:
Yongzhe LI
1
Author Information
1. 中国医学科学院北京协和医院检验，北京 100730
- Keywords:
Autoimmune diseases;
Lung diseases;
Nephrosis;
Diagnosis;
Biomarker
- From:
Chinese Journal of Laboratory Medicine
2024;47(9):981-986
- CountryChina
- Language:Chinese
-
Abstract:
Autoimmune nephropathies and lung dieases are conditions arised from the mistaken attacks of the immune system to the kidneys and lungs. Due to the complex pathogenesis and the variability and lack of specificity of clinical manifestations, there are many challenges on accurate diagnosis. While markers such as anti-MPO antibody, anti-PR3 antibody, and anti-PLA2R antibody have been widely used in clinical practise which obviously improved diagnostic precision and efficiency, there remains a deficiency in specific diagnostic indicators for conditions like seronegative membranous nephropathies, IgA nephropathies, alveolar protein deposition, interstitial lung disease, and pulmonary nodular disease. Thus, there is an urgent need to discover more sensitive and specific markers to provide basis for early diagnosis and personalized treatment guidance. For further quality improvment of diagnosis and treatment, we will focus on promoting normalization and standardization of testing methods to ensure quality control during analytical processes. This will bolster the laboratory analysis of the markers for autoimmune nephropathies and lung diseases markers, and will facilitate their clinical applications, so as to improve clinical diagnosis and treatment, and to elevate patients′ clinical outcomes as well as their quality of life.
